España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Ocugen
OCGN
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.6800
-0.02
-2.88%
At close: -
$0.6949
0.01
2.19%
After Hours: Feb 21, 7:53 PM EDT
Get Report
Comment
Q4 2024 Earnings in 10 days from now on Wed Mar 5th, before the market open
Ocugen (OCGN) Forecast
News
Earnings
Ocugen (OCGN) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Ocugen (NASDAQ:OCGN) Stock
Ocugen Stock (NASDAQ: OCGN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, February 13, 2025
Chardan Capital Maintains Buy on Ocugen, Main...
Benzinga Newsdesk
Expert Outlook: Ocugen Through The Eyes Of 4 Analysts
Benzinga Insights
HC Wainwright & Co. Maintains Buy on Ocugen, ...
Benzinga Newsdesk
Wednesday, February 12, 2025
Ocugen Competes Dosing In hase 2 ArMaDa Trial...
Benzinga Newsdesk
Monday, February 03, 2025
Ocugen's Gene Therapy OCU400 Gets EMA Opinion...
Benzinga Newsdesk
Monday, January 27, 2025
Ocugen shares are trading higher following FD...
Benzinga Newsdesk
Ocugen Gets FDA Clearance to Begin Phase 1 Tr...
Benzinga Newsdesk
Thursday, January 23, 2025
Chardan Capital Maintains Buy on Ocugen, Main...
Benzinga Newsdesk
Thursday, January 16, 2025
Ocugen Doses First Patient Dosed In Phase 1 T...
Benzinga Newsdesk
Monday, January 13, 2025
HC Wainwright & Co. Reiterates Buy on Ocugen,...
Benzinga Newsdesk
Ocugen Reveals Two-Year Results From Phase 1/...
Benzinga Newsdesk
Thursday, December 19, 2024
Ocugen Announced That The Data And Safety Mon...
Benzinga Newsdesk
Wednesday, November 20, 2024
Ocugen Announced That The European Medicines ...
Benzinga Newsdesk
Tuesday, November 19, 2024
Ocugen Announces Preliminary Data For OCU410l...
Benzinga Newsdesk
Monday, November 18, 2024
Chardan Capital Maintains Buy on Ocugen, Main...
Benzinga Newsdesk
Thursday, November 14, 2024
HC Wainwright & Co. Reiterates Buy on Ocugen,...
Benzinga Newsdesk
Monday, November 11, 2024
Navigating 4 Analyst Ratings For Ocugen
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Ocugen,...
Benzinga Newsdesk
Saturday, November 09, 2024
Chardan Capital Maintains Buy on Ocugen, Main...
Benzinga Newsdesk
Friday, November 08, 2024
Ocugen Q3 Sales $1.136M Beat $300.000K Estima...
Benzinga Newsdesk
Thursday, November 07, 2024
A Preview Of Ocugen's Earnings
Benzinga Insights
Ocugen Entered Into A New $30M Credit Facilit...
Benzinga Newsdesk
Monday, October 28, 2024
Ocugen Announced That It Will Host An In-pers...
Benzinga Newsdesk
Wednesday, October 23, 2024
HC Wainwright & Co. Reiterates Buy on Ocugen,...
Benzinga Newsdesk
Tuesday, October 22, 2024
The Data And Safety Monitoring Board Approved...
Benzinga Newsdesk
Tuesday, October 15, 2024
Maxim Group Initiates Coverage On Ocugen with...
Benzinga Newsdesk
Wednesday, October 09, 2024
Ocugen Announced That The US FDA Lifted The C...
Benzinga Newsdesk
Wednesday, August 28, 2024
Ocugen Announced That Dosing Is Complete In T...
Benzinga Newsdesk
Monday, August 26, 2024
Ocugen Receives Green Light from Health Canad...
Benzinga Newsdesk
Friday, August 09, 2024
Peering Into Ocugen's Recent Short Interest
Benzinga Insights
Thursday, August 08, 2024
Ocugen's Cash, Cash Equivalents, And Restrict...
Benzinga Newsdesk
Ocugen Q2 2024 GAAP EPS $(0.04) Beats $(0.06)...
Benzinga Newsdesk
Monday, August 05, 2024
Ocugen Announces Notification From FDA To Beg...
Benzinga Newsdesk
Thursday, August 01, 2024
Why Ocugen (OCGN) Stock Is Falling
Henry Khederian
Ocugen shares are trading lower after the com...
Benzinga Newsdesk
Reported Earlier, Ocugen Prices $35M Public O...
Benzinga Newsdesk
Wednesday, July 31, 2024
Ocugen shares are trading lower after the com...
Benzinga Newsdesk
Ocugen Announces Underwritten Public Offering...
Benzinga Newsdesk
Thursday, July 25, 2024
Ocugen Has Completed Dosing In Third Cohort O...
Benzinga Newsdesk
Friday, June 21, 2024
Ocugen Discloses Data And Safety Monitoring B...
Benzinga Newsdesk
Thursday, June 20, 2024
Ocugen shares are trading lower. The company ...
Benzinga Newsdesk
Ocugen Begins Phase 3 Trial for Gene Therapy ...
Benzinga Newsdesk
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Avi Kapoor
Friday, May 31, 2024
(OCGN) - Analyzing Ocugen's Short Interest
Benzinga Insights
Ocugen Announces Data And Safety Monitoring B...
Benzinga Newsdesk
Friday, May 17, 2024
DXC Technology Issues Weak Outlook, Joins Take-Two Interactive And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Avi Kapoor
Thursday, May 16, 2024
Nayax Posts Weak Q1 Results, Joins GameStop, Iris Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Avi Kapoor
Wednesday, May 15, 2024
Chardan Capital Maintains Buy on Ocugen, Main...
Benzinga Newsdesk
4 Analysts Assess Ocugen: What You Need To Know
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Ocugen,...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
